Related Experiment Video
Updated: Jul 7, 2026

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children
Eric K France1, Jason Glanz, Stanley Xu
1Department of Preventive Medicine, Kaiser Pemanente Colorado, Denver, CO 80231, USA. eric.k.france@kp.org
Insights
The measles-mumps-rubella (MMR) vaccine may increase the risk of immune thrombocytopenia purpura (ITP) in children. This study found that 76% of ITP cases in toddlers were linked to the MMR vaccine, causing 1 case per 40,000 doses.
Area of Science:
- Pediatric immunology
- Vaccine safety research
- Epidemiology
Background:
- Previous small studies suggested a link between the measles-mumps-rubella (MMR) vaccine and immune thrombocytopenia purpura (ITP).
- Further investigation was warranted to confirm this association and quantify the risk.
Purpose of the Study:
- To evaluate the association between the MMR vaccine and the incidence of ITP in children.
- To determine the risk of ITP following MMR vaccination in different age groups.
Main Methods:
- A retrospective cohort study using the Vaccine Safety Datalink database.
- Identified children aged 1-18 years who received the MMR vaccine.
- Defined ITP cases based on platelet count (< or = 50,000/microL) with clinical bleeding and normal blood counts.
- Calculated incidence rates and incident rate ratios (IRRs) for exposed and unexposed periods, focusing on ages 12-23 months.
Main Results:
- Over 1 million MMR vaccine doses were administered to 1,036,689 children, with 259 confirmed ITP cases.
- The incidence rate ratio for ITP was highest in children aged 12-15 months (IRR=7.10).
- Boys aged 12-15 months had a significantly higher IRR (14.59) compared to girls (3.22).
- Approximately 76% of ITP cases in 12-23 month olds were attributable to the MMR vaccine, estimating 1 case per 40,000 doses.
Conclusions:
- The MMR vaccine administered in the second year of life is associated with an increased risk of developing immune thrombocytopenia purpura.
- The findings highlight a specific risk period for ITP following MMR vaccination, particularly in young children.
Background:
The measles-mumps-rubella vaccine has been associated with immune thrombocytopenia purpura in 2 small studies.
Methods:
By using the Vaccine Safety Datalink, we identified measles-mumps-rubella-vaccinated children aged 1 to 18. A case of immune thrombocytopenia purpura was defined as a patient with a platelet count of < or = 50,000/microL with clinical bleeding and normal red and white blood cell indices. The immune thrombocytopenia purpura incidence rates during exposed (42 days after vaccination) and unexposed time periods were determined. A retrospective cohort of vaccinated children was used to determine incident rate ratios for children aged 1 to 18 years, 12 to 23 months, and 12 to 15 months.
Results:
A total of 1,036,689 children received 1,107,814 measles-mumps-rubella vaccinations; there were 259 confirmed patients with immune thrombocytopenia purpura. Because only 5 exposed cases occurred after age 2, analyses were limited to children aged 12 to 23 months. Exposed patients aged 12 to 23 months had lower median platelet counts than those who were unexposed and had similar median duration of illness (11 vs 10 days). The incident rate ratio was highest for children aged 12 to 15 months at 7.10. The incident rate ratio for boys aged 12 to 15 months was 14.59, and the incident rate ratio for girls in the same age group was 3.22. Seventy-six percent of immune thrombocytopenia purpura cases in children aged 12 to 23 months were attributable to measles-mumps-rubella vaccination. This vaccine causes 1 case of immune thrombocytopenia purpura per every 40,000 doses.
Conclusion:
Measles-mumps-rubella vaccine that is given in the second year of life is associated with an increased risk of immune thrombocytopenia purpura.
Related Concept Videos
Respiratory Syncytial Virus Disease
Vaccinations
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Rocky Mountain Spotted Fever
Chickenpox
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...